On July 2, TransThera Sciences-B (02617.HK) rose 6.93% in regular trading, reaching HK$12.29 per share, with turnover of HK$317 million.

On the news front, the company released two R&D progress announcements on July 1. First, its core product tinengotinib completed patient enrollment for a global multi-center registrational Phase III clinical trial as monotherapy for advanced cholangiocarcinoma, marking a critical milestone toward regulatory filing. Second, the company received NMPA approval to conduct a Phase II clinical trial of TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma, further broadening its hematologic oncology pipeline. Multiple clinical studies have confirmed that BTK inhibitors combined with anti-CD20 antibodies can enhance first-line treatment efficacy in mantle cell lymphoma.

The stock had previously experienced significant selling pressure following a major share unlock on June 23, when approximately 382 million restricted shares were released, causing the stock to plunge over 60% in two trading days. The company announced a share buyback plan of up to RMB 100 million on June 28 to stabilize market confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)